579 related articles for article (PubMed ID: 33568794)
1. Therapeutic pipeline in nonalcoholic steatohepatitis.
Vuppalanchi R; Noureddin M; Alkhouri N; Sanyal AJ
Nat Rev Gastroenterol Hepatol; 2021 Jun; 18(6):373-392. PubMed ID: 33568794
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis.
Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A
Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871
[TBL] [Abstract][Full Text] [Related]
3. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
Noureddin M; Anstee QM; Loomba R
Aliment Pharmacol Ther; 2016 Jun; 43(11):1109-23. PubMed ID: 27061197
[TBL] [Abstract][Full Text] [Related]
4. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.
Shi YW; Fan JG
Acta Pharmacol Sin; 2022 May; 43(5):1191-1199. PubMed ID: 34907360
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
Wattacheril J; Issa D; Sanyal A
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
[TBL] [Abstract][Full Text] [Related]
6. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
7. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
[TBL] [Abstract][Full Text] [Related]
8. How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark J; Tacke F
Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
[TBL] [Abstract][Full Text] [Related]
9. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
10. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
11. Emerging synthetic drugs for the treatment of liver cirrhosis.
Fallowfield JA; Jimenez-Ramos M; Robertson A
Expert Opin Emerg Drugs; 2021 Jun; 26(2):149-163. PubMed ID: 33856246
[No Abstract] [Full Text] [Related]
12. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.
Herring WL; Gould IG; Wittrup-Jensen V; Ertle J; Kuti E; Wolowacz S
J Comp Eff Res; 2022 Dec; 11(18):1349-1363. PubMed ID: 36317935
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
Esteban JPG; Asgharpour A
Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
[TBL] [Abstract][Full Text] [Related]
15. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
Fraile JM; Palliyil S; Barelle C; Porter AJ; Kovaleva M
Drug Des Devel Ther; 2021; 15():3997-4009. PubMed ID: 34588764
[TBL] [Abstract][Full Text] [Related]
17. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
Drenth JPH; Schattenberg JM
Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP; Patel J; Byrne CD
Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
[No Abstract] [Full Text] [Related]
19. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges.
Dufour JF; Caussy C; Loomba R
Gut; 2020 Oct; 69(10):1877-1884. PubMed ID: 32381514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
